The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
High-Content Phenotypic Profiling of Drug Response Signatures across Distinct Cancer Cells
Abstract
The application of high-content imaging in conjunction with multivariate clustering techniques has recently shown value in the confirmation of cellular activity and further characterization of drug mode of action following pharmacologic perturbation. However, such practical examples of phenotypic profiling of drug response published to date have largely been restricted to cell lines and phenotypic response markers that are amenable to basic cellular imaging. As such, these approaches preclude the analysis of both complex heterogeneous phenotypic responses and subtle changes in cell morphology across physiologically relevant cell panels. Here, we describe the application of a cell-based assay and custom designed image analysis algorithms designed to monitor morphologic phenotypic response in detail across distinct cancer cell types. We further describe the integration of these methods with automated data analysis workflows incorporating principal component analysis, Kohonen neural networking, and kNN classification to enable rapid and robust interrogation of such data sets. We show the utility of these approaches by providing novel insight into pharmacologic response across four cancer cell types, Ovcar3, MiaPaCa2, and MCF7 cells wild-type and mutant for p53. These methods have the potential to drive the development of a new generation of novel therapeutic classes encompassing pharmacologic compositions or polypharmacology in appropriate disease context. Mol Cancer Ther; 9(6); 1913–26. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Self-organized formation of topologically correct feature maps
Kohonen, T. (1982) · Biological Cybernetics · doi:10.1007/bf00337288 · Cited by 9,529
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 1×
“Acquired drug resistance and intrinsic heterogeneity among patients, tumor sites, and stage of disease represent significant challenges to the successful treatment of cancer with targeted pharmacologic agents (11 – 13).”
BackgroundBubb, M. R., Senderowicz, A. M., Sausville, E. A., Duncan, K. L., & Korn, E. D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36545-6 · Cited by 811
Multidimensional Drug Profiling By Automated Microscopy
Perlman, Z. E., Slack, M. D., Feng, Y., Mitchison, T. J., Wu, L. F., & Altschuler, S. J. (2004) · Science · doi:10.1126/science.1100709 · Cited by 660
An approach for extensibly profiling the molecular states of cellular subpopulations
Loo, L.-H., Lin, H.-J., Steininger, R. J., Wang, Y., Wu, L. F., & Altschuler, S. J. (2009) · Nature Methods · doi:10.1038/nmeth.1375 · Cited by 69
Cited by
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Data-analysis strategies for image-based cell profiling
Caicedo, J. C., Cooper, S., Heigwer, F., Warchal, S., Qiu, P., Molnar, C., Vasilevich, A. S., Barry, J. D., Bansal, H. S., Kraus, O., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4397 · Cited by 739
Screening out irrelevant cell-based models of disease
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525
Self-citationPhenotypic screening in cancer drug discovery — past, present and future
Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507
Image-based profiling for drug discovery: due for a machine-learning upgrade?
Chandrasekaran, S. N., Ceulemans, H., Boyd, J. D., & Carpenter, A. E. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00117-w · Cited by 389
Metadata
- Authors
- Caie, P. D., Walls, R. E., Ingleston-Orme, A., Daya, S., Houslay, T., Eagle, R., Roberts, M. E., & Carragher, N. O.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2010-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 1913-1926
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2104036010
- Cited by
- 171
- References
- 5
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-Content Phenotypic Profiling of Drug Response Signatures across Distinct Cancer Cells. https://app.cochat.ai/papers/10.1158/1535-7163.mct-09-1148
- The paper
- Caie, P. D., Walls, R. E., Ingleston-Orme, A., Daya, S., Houslay, T., Eagle, R., Roberts, M. E., & Carragher, N. O. (2010). High-Content Phenotypic Profiling of Drug Response Signatures across Distinct Cancer Cells. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-09-1148
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.